Patient compliance cost-effectiveness

Adequately powered, randomised, controlled studies to investigate the potential benefit of low-allergen domestic environments in patients with allergic disease are needed. Such studies should also address compliance, cost-effectiveness and be of adequate length (e.g. 12 months) and tailored for different socio-economic groups and age groups. 

Compared with monotherapy, combination therapy is relatively unstudied in terms of the effects on CHD event reduction and may reduce patient compliance through increased side effects and increased costs. When used appropriately and with proper precautions, however, they are effective in normalizing lipid abnormalities, particularly in patients who cannot tolerate adequate doses of statin therapy for more severe forms of dyslipidemia. 

Monotherapy with a PPI is not only more effective in patients not responding to an H2RA or prokinetic agent alone, but it also improves compliance with once-daily dosing and is ultimately more cost-effective. 

Virtually all therapeutic proteins must enter the blood in order to promote a therapeutic effect. Such products must usually be administered parenterally. However, research continues on the development of non-parenteral routes which may prove more convenient, less costly and obtain improved patient compliance. Alternative potential delivery routes include transdermal, nasal, oral and bucal approaches, although most progress to date has been recorded with pulmonary-based delivery systems (Chapter 4). An inhaled insulin product ( Exubera , Chapters 4 and 11) was approved in 2006 for the treatment of type I and II diabetes. 

The choice of an NSAID thus requires a balance of efficacy, cost-effectiveness, safety, and numerous personal factors (eg, other drugs also being used, concurrent illness, compliance, medical insurance coverage), so that there is no best NSAID for all patients. There may, however, be one or two best NSAIDs for a specific person. 

Solutions The reasons behind choosing solutions over other dosage forms are their favorable cost advantage, the simplicity of formulation development and production, and the high acceptance by patients [170], However, there are also a few drawbacks, such as rapid and extensive precorneal loss, high absorption via the conjunctiva and the nasolacrimal duct leading to systemic side effects, as well as the increased installation frequency resulting in low patient compliance. 

Considering compliance, adverse effects, and effectiveness, statins are the drugs of choice for patients with hypercholesterolemia because they are the most potent form of monotherapy and are cost-effective in patients with known... 

---